var data={"title":"Panitumumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Panitumumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/236279?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=panitumumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Panitumumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709195\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Dermatologic toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic toxicities occurred in 90% of patients and were severe (National Cancer Institute Common Toxicity Criteria [NCI-CTC] grade 3 and higher) in 15% of patients receiving panitumumab monotherapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343189\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vectibix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6826223\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vectibix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343193\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343261\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Establish <i>RAS</i> mutation status (to confirm <i>RAS</i> wild-type) prior to treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, metastatic, <i>RAS</i> wild-type:</b> IV: 6 mg/kg every 14 days as a single agent (Van Cutsem 2007) or in combination with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) (Douillard 2010; Douillard 2013); continue until disease progression or unacceptable toxicity (Douillard 2010; Van Cutsem 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, metastatic, <i>RAS</i> wild-type in combination with FOLFIRI (fluorouracil, leucovorin, and irinotecan; off-label combination):</b> IV: 6 mg/kg every 14 days; continue until disease progression or unacceptable toxicity (Peeters 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343262\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343263\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343264\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343265\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infusion reactions, mild-to-moderate (grade 1 or 2): Reduce the infusion rate by 50% for the duration of infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infusion reactions, severe (grade 3 or 4): Stop infusion; consider permanent discontinuation (depending on severity or persistence of reaction).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 toxicity (first occurrence): Withhold 1 to 2 doses; if reaction improves to &lt;grade 3, resume therapy at initial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 toxicity (second occurrence): Withhold 1 to 2 doses; if reaction improves to &lt;grade 3, resume therapy at 80% of initial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 toxicity (third occurrence): Withhold 1 to 2 doses; if reaction improves to &lt;grade 3, resume therapy at 60% of initial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 toxicity (fourth occurrence), grade 3 toxicity that does not recover to &lt;grade 3 after withholding 1 or 2 doses, or grade 4 toxicity: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocular toxicity (acute or worsening keratitis): Interrupt or discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pulmonary toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acute onset or worsening pulmonary symptoms: Interrupt treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Interstitial lung disease: Permanently discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343274\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vectibix: 100 mg/5 mL (5 mL); 400 mg/20 mL (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343191\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343266\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV infusion only; do not administer IV push or as a bolus. Administer via infusion pump through a low protein-binding 0.2 or 0.22 micrometer in-line filter. Doses &le;1,000 mg, infuse over 1 hour; if first infusion is tolerated, subsequent doses may be administered over 30 to 60 minutes. Doses &gt;1,000 mg, infuse over 90 minutes. Flush line with NS before and after infusion; do not mix or administer with other medications. Reduce infusion rate by 50% for mild to moderate infusion reactions (grades 1 and 2); stop infusion for severe infusion reactions (grades 3 and 4) and consider permanent discontinuation. Appropriate medical support for the management of infusion reactions should be readily available.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343195\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer (metastatic): </b>Treatment of patients with wild-type <i>RAS</i> (defined as wild-type in both <i>KRAS</i> and <i>NRAS</i> as determined by an approved test) metastatic colorectal cancer (mCRC), either as first-line therapy in combination with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or as a single agent following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Panitumumab is not indicated for the treatment of patients with <i>RAS</i>-mutant mCRC or for whom <i>RAS</i> mutation status is unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469580\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Colorectal cancer, metastatic, KRAS wild-type (in combination with other chemotherapy agents)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471958\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Panitumumab may be confused with pertuzumab</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343245\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Monotherapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Fatigue (26%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Skin toxicity (90%; grades 3/4: 15%), erythema (66%; grades 3/4: 6%), pruritus (58%; grades 3/4: 3%), acneiform eruption (57%; grades 3/4: 7%), paronychia (25%; grades 3/4: 2%), rash (22%; grades 3/4: 1%), skin fissure (20%; grades 3/4: 1%), exfoliative dermatitis (18%; grades 3/4: 2%), acne vulgaris (14%; grades 3/4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Hypomagnesemia (grades 3/4: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Nausea (23%), diarrhea (21%; grades 3/4: 2%), vomiting (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ophthalmic: Ocular toxicity (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Dyspnea (18%), cough (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Pulmonary embolism (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Chills (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Nail toxicity (10%), xeroderma (10%), desquamation (9%; grades 3/4: &lt;1%), dermal ulcer (6%; grades 3/4: &lt;1%), pustular rash (4%), papular rash (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Dehydration (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Mucositis (7%), stomatitis (7%), xerostomia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunologic: Antibody formation (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ophthalmic: Abnormal eyelash growth (6%), conjunctivitis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Epistaxis (4%), interstitial pulmonary disease (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Infusion related reaction (3%; grades 3/4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%: Hypersensitivity reaction, pulmonary fibrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Combination therapy with FOLFOX:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Skin rash (56%; grades 3/4: 17% to 26%), acneiform eruption (32%; grades 3/4: 10%), pruritus (23%; grades 3/4: &lt;1%), paronychia (21%; grades 3/4: 3%), xeroderma (21%; grades 3/4: 2%), erythema (16%; grades 3/4: 2%), skin fissure (16%; grades 3/4: &lt;1%), alopecia (15%), acne vulgaris (14%; grades 3/4: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Hypomagnesemia (30%), hypokalemia (21%), weight loss (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Diarrhea (62%), anorexia (36%), abdominal pain (28%), stomatitis (27%), mucosal inflammation (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Weakness (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ophthalmic: Conjunctivitis (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Epistaxis (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Deep vein thrombosis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Fatigue (&ge;1%), paresthesia (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Nail disorder (10%; grades 3/4: 1%), palmar-plantar erythrodysesthesia (9%; grades 3/4: 1%), cellulitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Dehydration (8%), hypocalcemia (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypersensitivity: Hypersensitivity (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Local: Localized infection (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%: Antibody development</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postmarketing and/or case reports (mono- and combination therapy):</b> Abscess, angioedema, bullous skin disease (mucocutaneous), corneal ulcer, keratitis, necrotizing fasciitis, sepsis, skin necrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343241\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> History of severe or life-threatening hypersensitivity reactions to panitumumab or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343242\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: <b>[US Boxed Warning]: Dermatologic toxicities have been reported in 90% of patients receiving single agent panitumumab and were severe (grade 3 or higher) in 15% of patients;</b> may include dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures. Severe skin toxicities may be complicated by infection, sepsis, necrotizing fasciitis, or abscesses. The median time to development of skin (or ocular) toxicity was 2 weeks, with resolution ~12 weeks after discontinuation. The severity of dermatologic toxicity is predictive for response; grades 2 to 4 skin toxicity correlates with improved progression free survival and overall survival, compared to grade 1 skin toxicity (Peeters 2009; Van Cutsem 2007). Monitor all dermatologic toxicities for development of inflammation or infection. Rare cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported; bullous mucocutaneous disease (life-threatening/fatal) have been observed. Withhold treatment for severe or life-threatening dermatologic or soft tissue toxicities associated with severe/life-threatening inflammatory or infectious complications; dermatologic toxicity may require dose reduction or permanent discontinuation. Patients should minimize sunlight exposure and wear sunscreen and protective clothing/hat; sunlight may exacerbate skin reactions. Nail toxicity has also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diarrhea: May cause diarrhea; the incidence and severity of chemotherapy-induced diarrhea is increased with combination chemotherapy. Severe diarrhea and dehydration (which may lead to acute renal failure) has been observed with panitumumab in combination with chemotherapy. Gastric mucosal toxicity has also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte depletion: Magnesium and/or calcium depletion may occur during treatment (may be delayed; hypomagnesemia occurred &ge;8 weeks after completion of panitumumab) and after treatment is discontinued; electrolyte repletion may be necessary. Monitor for hypomagnesemia and hypocalcemia during treatment and for at least 8 weeks after completion. Hypokalemia has also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Severe infusion reactions (bronchospasm, dyspnea, fever, chills, and hypotension) have been reported in ~1% of patients; fatal infusion reactions have been reported with postmarketing surveillance. Discontinue infusion for severe reactions; permanently discontinue in patients with persistent severe infusion reactions. Appropriate medical support for the management of infusion reactions should be readily available. Mild to moderate infusion reactions are managed by slowing the infusion rate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular toxicity: Keratitis and ulcerative keratitis (known risk factors for corneal perforation) have occurred. Monitor for evidence of ocular toxicity; interrupt or discontinue treatment for acute or worsening keratitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Pulmonary fibrosis and interstitial lung disease have been observed (rarely) in clinical trials; fatalities have been reported. Interrupt treatment for acute onset or worsening of pulmonary symptoms; permanently discontinue treatment if interstitial lung disease is confirmed. Patients with a history of or evidence of interstitial pneumonitis or pulmonary fibrosis were excluded from most clinical trials; consider the benefits of therapy versus the risk of pulmonary complications in such patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Colorectal cancer and <i>RAS</i> mutation status: Confirm absence of <i>RAS</i> mutation prior to treatment; patients with codons 12 and 13 (exon 2), codons 59 and 61 (exon 3), or codons 117 and 146 (exon 4) <i>RAS</i> (<i>KRAS</i> or <i>NRAS</i>) mutations are unlikely to benefit from EGFR inhibitor therapy. Panitumumab is not indicated in patients with <i>RAS</i> mutation-positive metastatic colorectal cancer or patients in whom <i>RAS</i> mutation status is unknown. Utilizing an anti-EGFR-directed antibody in patients whose tumors contain <i>RAS</i> mutations resulted in increased toxicity without clinical benefit. In a study of FOLFOX4 (fluorouracil, leucovorin, and oxaliplatin) &plusmn; panitumumab, patients with a <i>KRAS</i> mutation who received panitumumab with FOLFOX4 experienced a significantly shortened progression-free survival (Douillard 2010). In addition, a subset analysis of patients with wild-type <i>KRAS</i> identified additional <i>RAS</i> (<i>KRAS</i> [exons 3 and 4] or <i>NRAS</i> [exons 2, 3, 4]) mutations; progression-free survival and overall survival were significantly shortened in patients with <i>RAS</i> mutations who received FOLFOX4 in combination with panitumumab (Douillard 2013). The American Society of Clinical Oncology (ASCO) provisional clinical opinion update recommends that all patients with metastatic colorectal cancer who are candidates for anti-EGFR therapy should be tested (in a certified lab) for mutations in both <i>KRAS</i> and <i>NRAS</i> exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146); anti-EGFR monoclonal antibody therapy should only be considered in patients whose tumors lack mutations after extended <i>RAS</i> testing (Allegra 2016). Information on tests approved for detection of RAS mutation is available at <a target=\"_blank\" href=\"http://www.fda.gov/CompanionDiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IPc+kYYsON95PtA1EteUbfjUoJYJ+uveJw2PtFUTXMkK&amp;TOPIC_ID=10336\" target=\"_blank\">www.fda.gov/CompanionDiagnostics</a>. Panitumumab is also reported to be ineffective in patients with BRAF V600E mutation (Di Nicolantonio 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bevacizumab and combination chemotherapy: In a study of bevacizumab with combination chemotherapy &plusmn; panitumumab, the use of panitumumab resulted in decreased progression-free and overall survival and significantly increased toxicity compared to regimens without panitumumab (Hecht 2009). Toxicities included rash/acneiform dermatitis, diarrhea/dehydration, electrolyte disturbances, mucositis/stomatitis, and an increased incidence of pulmonary embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Patients &gt;65 years of age receiving panitumumab plus FOLFOX experienced a higher incidence of serious adverse events including severe diarrhea.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299817\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222127\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10336&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343197\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Based on animal reproduction studies and on the mechanism of action, panitumumab may cause fetal harm if administered during pregnancy. Panitumumab is a human IgG monoclonal antibody and may be transferred across the placenta. Because panitumumab inhibits epidermal growth factor (EGF), a component of fetal development, adverse effects on pregnancy would be expected. Females of reproductive potential should use effective contraception during treatment and for at least 2 months after the last dose. Panitumumab may reduce fertility in females of reproductive potential (based on animal data).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In the US and Canada, women who become pregnant during panitumumab treatment are encouraged to enroll in Amgen's Pregnancy Surveillance Program (US: 1-800-772-6436; Canada: 1-866-512-6436).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343200\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if panitumumab is present in breast milk. Panitumumab is an IgG monoclonal antibody and maternal IgG immunoglobulins are excreted in breast milk; however, breast milk antibodies are not expected to enter neonatal and infant circulation in substantial amounts. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends women not breastfeed during therapy and for 2 months after the final panitumumab dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In the US and Canada, women who breastfeed during panitumumab treatment are encouraged to enroll in Amgen's Lactation Surveillance Program (US: 1-800-772-6436; Canada: 1-866-512-6436).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343269\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>RAS</i> genotyping of tumor tissue to establish <i>RAS</i> mutation status and confirm <i>RAS</i> wild-type (prior to treatment initiation). Monitor serum electrolytes, including magnesium and calcium (periodically during and for at least 8 weeks after therapy), and potassium. Monitor vital signs and temperature before, during, and after infusion. Monitor for skin toxicity, for evidence of ocular toxicity, and for acute onset or worsening pulmonary symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343255\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Panitumumab is a recombinant human IgG2 monoclonal antibody which binds specifically to the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands. Binding to the EGFR blocks phosphorylation and activation of intracellular tyrosine kinases, resulting in inhibition of cell survival, growth, proliferation, and transformation. EGFR signal transduction may result in <i>KRAS</i> and <i>NRAS</i> wild-type activation; cells with <i>RAS</i> mutations appear to be unaffected by EGFR inhibition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343257\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Half-life elimination: ~7.5 days (range: 4 to 11 days)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5685563\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vectibix Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (5 mL): $1,424.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/20 mL (20 mL): $5,699.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6875345\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Vectibix (AE, AR, AT, AU, BB, BE, BR, CH, CL, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FR, GB, GR, GT, HK, HN, HR, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, PA, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. <i>J Clin Oncol.</i> 2016;34(2):179-185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/26438111/pubmed\" target=\"_blank\" id=\"26438111\">26438111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amado RG, Wolf M, Peeters M, et al. Wild-Type KRAS is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. <i>J Clin Oncol</i>. 2008;26(10):1626-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/18316791/pubmed\" target=\"_blank\" id=\"18316791\">18316791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. <i>J Clin Oncol</i>. 2008;26(35):5705-5712.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/19001320/pubmed\" target=\"_blank\" id=\"19001320\">19001320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. <i>N Engl J Med</i>. 2013;369(11):1023-1034.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/24024839/pubmed\" target=\"_blank\" id=\"24024839\">24024839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douillard JY, Siena S, Cassidy J, et al. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone as First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. <i>J Clin Oncol</i>. 2010;28(31):4697-4705.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/20921465/pubmed\" target=\"_blank\" id=\"20921465\">20921465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hecht JR, Mitchell E, Chidiac T, et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. <i>J Clin Oncol</i>. 2009;27(5):672-680.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/19114685/pubmed\" target=\"_blank\" id=\"19114685\">19114685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20921462\"></a>Peeters M, Price TJ, Cervantes A, et al. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer. <i>J Clin Oncol</i>. 2010; 28(31):4706-4713.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/20921462/pubmed\" target=\"_blank\" id=\"20921462\">20921462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peeters M, Siena S, Van Cutsem E, et al. Association of Progression-Free Survival, Overall Survival, and Patient-Reported Outcomes by Skin Toxicity and KRAS Status in Patients Receiving Panitumumab Monotherapy. <i>Cancer</i>. 2009, 115(7):1544-1554.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/19189371/pubmed\" target=\"_blank\" id=\"19189371\">19189371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Segaert S and Van Cutsem E. Clinical Signs, Pathophysiology and Management of Skin Toxicity During Therapy with Epidermal Growth Factor Receptor Inhibitors. <i>Ann Oncol</i>. 2005;16(9):1425-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/16012181/pubmed\" target=\"_blank\" id=\"16012181\">16012181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Cutsem E, Peeters M, Siena S, et al. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. <i>J Clin Oncol</i>. 2007;25(13):1658-1664.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/17470858/pubmed\" target=\"_blank\" id=\"17470858\">17470858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vectibix (panitumumab) [prescribing information]. Thousand Oaks, CA: Amgen; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vectibix (panitumumab) [prescribing information]. Mississauga, Ontario, Canada: Amgen Canada Inc; March 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10336 Version 134.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709195\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3343189\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F6826223\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3343193\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3343261\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3343262\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F3343263\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F3343264\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F3343265\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F3343274\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3343191\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3343266\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3343195\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469580\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14471958\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3343245\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3343241\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3343242\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299817\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222127\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3343197\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3343200\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3343269\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3343255\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3343257\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5685563\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6875345\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10336|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=panitumumab-patient-drug-information\" class=\"drug drug_patient\">Panitumumab: Patient drug information</a></li></ul></div></div>","javascript":null}